CellCept® Dose Adjustment Versus Fixed Dose (Standard Care) in Renal Transplant Recipients

Inclusion Criteria: * Male or female subjects, between 18 to 70 years of age at the time of enrollment. * Patient who received first or second renal transplant. * Patients who are 0-14 days post transplant. * Patients capable of understanding the purposes and risks of the study who signed a written informed consent to participate and to comply with the requirements of the study. Exclusion Criteria: * Women lactating, pregnant or of childbearing potential not using a reliable contraceptive method before beginning study drug therapy, during therapy and for 4 months following their last dose of the study drug therapy. * Patients with severe diarrhea or other gastrointestinal disorders that might interfere with their ability to absorb oral medication, including diabetic patients with previously diagnosed diabetic gastroenteropathy. * Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study. * Patients with evidence of an active systemic infection requiring the continued use of antibiotics or evidence of an HIV infection, or the presence of a chronic active hepatitis B (HBs-Ag positive) or C. * Current or historic Panel Reactive Antibody (PRA) \>50% * Positive crossmatch (irrespective of method). * Cold ischemia time of the graft of more than 30 hours. * Patients who had received an investigational new drug within the last three months at the time of enrollment. * Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ other than kidney. * Patients with any known hypersensitivity to MPA, EC-MPS or other components of the formulation (e.g. lactose). * Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \<1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline. * Patients with a history of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin. * Previous exposure to EC-MPS.